AI Market Mood: Stock Dashboard
SMMT
Fundamental
Company: Summit Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: Large
Index: -
P/E: -
EPS (ttm): -1.60
Insider Own: 83.15%
Shs Outstand: 776.02M
Perf Week: 5.12%
Market Cap: 10.67B
Forward P/E: -
EPS next Y: -1.10
Insider Trans: 1.23%
Shs Float: 130.76M
Perf Month: -13.25%
Enterprise Value: 10.09B
PEG: -
EPS next Q: -0.27
Inst Own: 15.52%
Short Float: 27.63%
Perf Quarter: -12.53%
Income: -1.21B
P/S: -
EPS this Y: 24.45%
Inst Trans: 1.27%
Short Ratio: 7.46
Perf Half Y: -20.20%
Sales: 0.00M
P/B: 19.55
EPS next Y Percentage: -1.34%
ROA: -233.81%
Short Interest: 36.13M
Perf YTD: -21.38%
Book/sh: 0.70
P/C: 17.82
EPS next 5Y: 30.13%
ROE: -270.95%
52W High: 30.98 -55.62%
Perf Year: -31.80%
Cash/sh: 0.77
P/FCF: -
EPS past 3/5Y: -52.45% -13.76%
ROIC: -214.31%
52W Low: 12.55 9.56%
Perf 3Y: 561.06%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -
Volatility W: 6.44%
Volatility M: 7.11%
Perf 5Y: 108.02%
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: -384.68%
Oper. Margin: -
ATR (14): 1.10
Perf 10Y: 69.97%
Dividend Ex-Date: -
Quick Ratio: 7.41
Sales Y/Y TTM: -
Profit Margin: -
RSI (14): 37.16
Recom: 1.69
Dividend Gr. 3/5Y: - -
Current Ratio: 7.41
EPS Q/Q: -186.74%
SMA20: -9.25%
Beta: -1.23
Target Price: 29.69
Payout: -
Debt/Eq: 0.04
Sales Q/Q: -
SMA50: -24.00%
Rel Volume: 1.80
Prev Close: 14.07
Employees: 265
LT Debt/Eq: 0.03
Earnings: Apr 30 AMC
SMA200: -23.44%
Avg Volume: 4.84M
Price: 13.75
IPO: Mar 05, 2015
Option/Short: Yes / Yes
EPS/Sales Surpr.: 10.85% -100.00%
Trades:
Volume: 8,702,671
Change: -2.27%
Technical:
Latest News:
Citigroup Initiates Coverage of Summit Therapeutics (SMMT) with Buy Recommendation very bullish
SMMT
Summary: Citigroup initiated coverage of Summit Therapeutics with a Buy recommendation, projecting a 53.67% upside potential. Various funds and institutions are increasing their positions, with a bullish sentiment indicated by the put/call ratio of 0.35.
Full article2024-05-08T17:42:16Z